Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis

English version České info

Background:
Observational studies of a putative association between hormonal contraception (HC) and HIV acquisition have produced conflicting results. We conducted an individual participant data (IPD) meta-analysis of studies from sub-Saharan Africa to compare the incidence of HIV infection in women using combined oral contraceptives (COCs) or the injectable progestins depot-medroxyprogesterone acetate (DMPA) or norethisterone enanthate (NET-EN) with women not using HC.

Methods and Findings:
Eligible studies measured HC exposure and incident HIV infection prospectively using standardized measures, enrolled women aged 15–49 y, recorded ≥15 incident HIV infections, and measured prespecified covariates. Our primary analysis estimated the adjusted hazard ratio (aHR) using two-stage random effects meta-analysis, controlling for region, marital status, age, number of sex partners, and condom use. We included 18 studies, including 37,124 women (43,613 woman-years) and 1,830 incident HIV infections. Relative to no HC use, the aHR for HIV acquisition was 1.50 (95% CI 1.24–1.83) for DMPA use, 1.24 (95% CI 0.84–1.82) for NET-EN use, and 1.03 (95% CI 0.88–1.20) for COC use. Between-study heterogeneity was mild (I² < 50%). DMPA use was associated with increased HIV acquisition compared with COC use (aHR 1.43, 95% CI 1.23–1.67) and NET-EN use (aHR 1.32, 95% CI 1.08–1.61). Effect estimates were attenuated for studies at lower risk of methodological bias (compared with no HC use, aHR for DMPA use 1.22, 95% CI 0.99–1.50; for NET-EN use 0.67, 95% CI 0.47–0.96; and for COC use 0.91, 95% CI 0.73–1.41) compared to those at higher risk of bias (p_interaction = 0.003). Neither age nor herpes simplex virus type 2 infection status modified the HC–HIV relationship.

Conclusions:
This IPD meta-analysis found no evidence that COC or NET-EN use increases women’s risk of HIV but adds to the evidence that DMPA may increase HIV risk, underscoring the need for additional safe and effective contraceptive options for women at high HIV risk. A randomized controlled trial would provide more definitive evidence about the effects of hormonal contraception, particularly DMPA, on HIV risk.

Vyšlo v časopise: Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. PLoS Med 12(1): e32767. doi:10.1371/journal.pmed.1001778
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001778

Souhrn

Zdroje

1. Morrison CS, Turner AN, Jones LB (2009) Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 23: 263–284. doi: 10.1016/j.bpobgyn.2008.11.004 19211309

2. Morrison CS, Nanda K (2012) Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis 12: 2–3. doi: 10.1016/S1473-3099(11)70254-7 21975268

3. Polis CB, Curtis KM (2013) Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 13: 797–808. doi: 10.1016/S1473-3099(13)70155-5 23871397

4. Polis CB, Phillips SJ, Curtis KM, Westreich DJ, Steyn PS, et al. (2014) Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 90: 360–390. doi: 10.1016/j.contraception.2014.07.009 25183264

5. Abdool K, Abdool K, Frohlich J, Grobler A, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168–1174. doi: 10.1126/science.1193748

6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411–422. doi: 10.1056/NEJMoa1202614 22784040

7. Marazzo J, Cates W Jr (2011) Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis 53: 64–78. doi: 10.1093/cid/cir695

8. Petruney T, Robinson E, Reynolds H, Wilcher R, Cates W (2008) Contraception is the best kept secret for prevention of mother-to-child HIV transmission. Bull World Health Organ 86: B. doi: 10.2471/BLT.08.051458 18568260

9. United Nations Department of Economic and Social Affairs Poulation Division (2011) World Contraceptive Use 2011. New York: United Nations.

10. Kaushic C, Roth KL, Anipindi V, Xiu F (2011) Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J Reprod Immunol 88: 204–209. doi: 10.1016/j.jri.2010.12.004 21296427

11. World Health Organization (2012) Hormonal contraception and HIV: technical statement. Geneva: World Health Organization.

12. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, et al. (2005) Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2: 209–217. doi: 10.1191/1740774505cn087oa 16279144

13. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097. doi: 10.1371/journal.pmed.1000097 19621072

14. Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340: c221. doi: 10.1136/bmj.c221 20139215

15. Myer L, Denny L, Wright TC, Kuhn L (2007) Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int J Epidemiol 36: 166–174. doi: 10.1093/ije/dyl251 17175547

16. Watson-Jones D, Baisley K, Weiss H, Tanton C, Changalucha J, et al. (2009) Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania. AIDS 23: 415–422. doi: 10.1097/QAD.0b013e32831ef523 19114859

17. Heffron R, Donnell D, Rees H, Celum C, Mugo N, et al. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 12: 19–26. doi: 10.1016/S1473-3099(11)70247-X 21975269

18. Morrison C, Skoler-Karpoff S, Kwok C, Chen P, van de Wijgert J, et al. (2012) Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS 26: 497–504. doi: 10.1097/QAD.0b013e32834fa13d 22156973

19. Crook AM, Ford D, Gafos M, Hayes R, Kamali A, et al. (2014) Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod 29: 1810–1817. doi: 10.1093/humrep/deu113 24838704

20. McCoy S, Zheng W, Montgomery E, Blanchard K, van der Straten A, et al. (2013) Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 27: 1001–1009. doi: 10.1097/QAD.0b013e32835da401 23698064

21. Low N, Chersich M, Schmidlin K, Egger M, Francis S, et al. (2011) Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med 8: e1000416. doi: 10.1371/journal.pmed.1000416 21358808

22. Phillips SJ, Curtis KM, Polis CB (2013) Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS 27: 787–794. doi: 10.1097/QAD.0b013e32835bb672 23135169

23. Wells G, Shea B, O’Connell D, Peterson J, Welch V, et al. (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 18 December 2014.

24. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52: 377–384. doi: 10.1136/jech.52.6.377 9764259

25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4: e296. doi: 10.1371/journal.pmed.0040296 17941714

26. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012. doi: 10.1001/jama.283.15.2008 10789670

27. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, et al. (2011) GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: 383–394. doi: 10.1016/j.jclinepi.2010.04.026 21195583

28. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558. doi: 10.1002/sim.1186 12111919

29. Smith CT, Williamson PR, Marson AG (2005) Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 24: 1307–1319. doi: 10.1002/sim.2050 15685717

30. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, et al. (2007) Hormonal contraception and the risk of HIV acquisition. AIDS 21: 85–95. doi: 10.1097/QAD.0b013e3280117c8b 17148972

31. Morrison C, Chen P, Kwok C, Richardson B, Chipato T, et al. (2010) Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 24: 1778–1781. doi: 10.1097/QAD.0b013e32833a2537 20588106

32. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, et al. (2007) Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 21: 1771–1777. doi: 10.1097/QAD.0b013e328270388a 17690576

33. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, et al. (2004) Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 291: 2555–2562. doi: 10.1001/jama.291.21.2555 15173146

34. Vallely A, Kasindi S, Hambleton IR, Knight L, Chirwa T, et al. (2007) Microbicides development program, Tanzania-baseline characteristics of an occupational cohort and reattendance at 3 months. Sex Transm Dis 34: 638–643. doi: 10.1097/OLQ.0b013e3180325120 17717482

35. Kumwenda N, Kemewenda J, Kafulafula G, Makanani B, Taulo F, et al. (2008) HIV-1 incidence among women of reproductive age in Malawi. Int J STD AIDS 19: 339–341. doi: 10.1258/ijsa.2007.007165 18482966

36. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, et al. (2007) Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 370: 251–261. doi: 10.1016/S0140-6736(07)60950-7 17631387

37. Delany-Moretlwe S, Rees H (2010) Tshireletso study for women’s health. Microbicide feasibility study. Protocol. Hillbrow (South Africa): Reproductive Health Research Unit, University of Witwatersrand.

38. McGrath N, Chimbwete C, Bennish M, Cassol S, Nunn A, et al. (2014) A feasibility study in preparation for phase III microbicide trials in the Hlabisa sub-district, South Africa. http://www.africacentre.ac.za/Portals/0/Researchers/microbicide_protocol_5.0.pdf. Accessed 16 April 2014.

39. Martin HLJ, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, et al. (1998) Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 178: 1053–1059. doi: 10.1086/515654 9806034

40. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, et al. (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358: 1560–1571. doi: 10.1056/NEJMoa0800260 18337596

41. Myer L, Denny L, de Souza M, Wright TC Jr, Kuhn L (2006) Distinguishing the temporal association between women’s intravaginal practices and risk of human immunodeficiency virus infection: a prospective study of South African women. Am J Epidemiol 163: 552–560. doi: 10.1093/aje/kwj071 16443804

42. Kumwenda N, Hoffman I, Chirenje M, Kelly C, Coletti A, et al. (2006) HIV incidence among women of reproductive age in Malawi and Zimbabwe. Sex Transm Dis 33: 646–651. doi: 10.1097/01.olq.0000223283.27142.9f 16773032

43. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372: 1977–1987. doi: 10.1016/S0140-6736(08)61842-5 19059048

44. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, et al. (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376: 1329–1337. doi: 10.1016/S0140-6736(10)61086-0 20851460

45. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360: 971–977. doi: 10.1016/S0140-6736(02)11079-8 12383665

46. Karim QA, Kharsany AB, Frohlich JA, Werner L, Mashego M, et al. (2011) Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 40: 922–930. doi: 10.1093/ije/dyq176 21047913

47. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399–410. doi: 10.1056/NEJMoa1108524 22784037

48. Kapiga SH, Ewings FM, Ao T, Chilongani J, Mongi A, et al. (2013) The epidemiology of HIV and HSV-2 infections among women participating in microbicide and vaccine feasibility studies in Northern Tanzania. PLoS ONE 8: e68825. doi: 10.1371/journal.pone.0068825 23874780

49. Vandepitte J, Bukenya J, Weiss HA, Nakubulwa S, Francis SC, et al. (2011) HIV and other sexually transmitted infections in a cohort of women involved in high-risk sexual behavior in Kampala, Uganda. Sex Transm Dis 38: 316–323. 23330152

50. Feldblum P, Lie C, Weaver M, Van Damme L, Halpern V, et al. (2010) Baseline factors associated with incident HIV and STI in four microbicide trials. Sex Transm Dis 37: 594–601. 20879087

51. Ungchusak K, Rehle T, Thammapornpilap P, Spiegelman D, Brinkmann U, et al. (1996) Determinants of HIV infection among female commercial sex workers in northeastern Thailand: results from a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 12: 500–507. doi: 10.1097/00042560-199608150-00010 8757428

52. Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, et al. (2003) Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 17: 233–240. doi: 10.1097/00002030-200301240-00014 12545084

53. Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ (1998) The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 12: 75–84. doi: 10.1097/00002030-199801000-00009 9456257

54. Reid S, Dai J, Wang J, Sichalwe B, Akpomiemie G, et al. (2010) Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr 53: 606–613. doi: 10.1097/QAI.0b013e3181bc4869 19838129

55. Bulterys M, Chao A, Habimana P, Dushimimana A, Nawrocki P, et al. (1994) Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS 8: 1585–1591. doi: 10.1097/00002030-199411000-00010 7848595

56. Kilmarx PH, Limpakarnjanarat K, Mastro TD, Saisorn S, Kaewkungwal J, et al. (1998) HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. AIDS 12: 1889–1898. doi: 10.1097/00002030-199814000-00021 9792390

57. Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, et al. (2007) Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 75: 461–467. doi: 10.1016/j.contraception.2007.02.002 17519153

58. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, et al. (2011) Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25: 957–966. doi: 10.1097/QAD.0b013e32834541d9 21330907

59. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362: 427–439. doi: 10.1056/NEJMoa0904849 20089951

60. Lutalo T, Musoke R, Kong X, Makumbi F, Serwadda D, et al. (2013) Effects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS 27 (Suppl 1): S27–S34. doi: 10.1097/QAD.0000000000000045 24088681

61. Chirenje M, Kelly C, Ramjee G, Nyaradzo M, Coletti A, et al. (2012) Association between hormonal contraception and HIV infection in HPTN 035 [abstract]. International Microbicides Conference; 15–18 Apr 2012; Sydney Australia.

62. Noguchi L, Richardson B, Chirenje Z, Ramjee G, Nair G, et al. (2014) Injectable contraception and HIV acquisition in the VOICE Study (MTN-003) [abstract]. Conference on Retroviruses and Opportunistic Infection 2014s; 3–6 Mar 2014; Boston, Massachusetts, US.

63. Wand H, Ramjee G (2012) The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS 26: 375–380. doi: 10.1097/QAD.0b013e32834f990f 22156970

64. Jones AP, Riley RD, Williamson PR, Whitehead A (2009) Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials 6: 16–27. doi: 10.1177/1740774508100984 19254930

65. Werawatgoompa S, Vaivanijkul B, Leepipatpaiboon S, Channiyom K, Virutamasen P, et al. (1980) The effect of injectable norethisterone oenanthate on ovarian hormones in Thai women. Contraception 21: 299–309. doi: 10.1016/0010-7824(80)90008-6 7389353

66. Fotherby K, Hamawi A, Howard G, Bye PG, Elder M (1984) Pharmacokinetics of different doses of norethisterone oenanthate. Contraception 29: 325–333. doi: 10.1016/0010-7824(84)90066-0 6744856

67. Wira CR, Fahey JV (2008) A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 22: 1909–1917. doi: 10.1097/QAD.0b013e3283060ea4 18784454

68. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, et al. (2003) Classification and pharmacology of progestins. Maturitas 46 (Suppl 1): S7–S16. doi: 10.1016/j.maturitas.2003.09.014 14670641

69. Hapgood JP, Tomasicchio M (2010) Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis. Arch Virol 155: 1009–1019. doi: 10.1007/s00705-010-0678-0 20446002

70. Huijbregts R, Michel K, Hel Z (2014) Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception 90: 123–129. doi: 10.1016/j.contraception.2014.02.006 24674041

71. van de Wijgert JH, Verwijs MC, Turner AN, Morrison CS (2013) Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 27: 2141–2153. doi: 10.1097/QAD.0b013e32836290b6 23660575

72. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, et al. (2000) Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 96: 431–439. doi: 10.1016/S0029-7844(00)00906-6 10960638

73. Bahamondes L, Trevisan M, Andrade L, Marchi NM, Castro S, et al. (2000) The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62: 23–27. doi: 10.1016/S0010-7824(00)00132-3 11024225

74. Hel Z, Stringer E, Mestecky J (2010) Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 31: 79–97. doi: 10.1210/er.2009-0018 19903932

75. Trunova N, Tsai L, Tung S, Schneider E, Harouse J, et al. (2006) Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology 352: 169–177. doi: 10.1016/j.virol.2006.04.004 16730772

76. Morrison C, Fichorova RN, Mauck C, Chen PL, Kwok C, et al. (2014) Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr 66: 109–117. 24413042

77. Viechtbauer W, Cheung MWL (2010) Outlier and influence diagnostics for meta-analysis. Res Synth Methods 1: 112–125. doi: 10.1002/jrsm.11

78. Hernán M, Brumback B, Robins JM (2001) Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc 96: 440–448. doi: 10.1198/016214501753168154

79. Robins J (1997) Causal inference from complex longitudinal data. In: Berkane M, editor. Latent variable modeling and applications to causality. Lecture notes in statistics 120. New York: Springer Verlag. pp. 69–117.

80. Cates W, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Consortium (2014) Research on hormonal contraception and HIV. Lancet 383: 303–304. doi: 10.1016/S0140-6736(14)60097-0 24461116

81. Rees H (2014) DMPA and HIV: why we need a trial. Contraception 90: 354–356. doi: 10.1016/j.contraception.2014.08.007